Co-delivery of siRNA and doxorubicin to cancer cells from additively manufactured implants

Tumors in load bearing bone tissue are a major clinical problem, in part because surgical resection invokes a dilemma whether to resect aggressively, risking mechanical failure, or to resect conservatively, risking cancer recurrence due to residual malignant cells. A chemo-functionalized implant, ca...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:RSC advances 2015-11, Vol.5 (123), p.101718-101725
Hauptverfasser: Chen, Muwan, Andersen, Morten Oe, Dillschneider, Philipp, Chang, Chi-Chih, Gao, Shan, Le, Dang QS, Yang, Chuanxu, Hein, San, Buenger, Cody, Kjems, Joergen
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Tumors in load bearing bone tissue are a major clinical problem, in part because surgical resection invokes a dilemma whether to resect aggressively, risking mechanical failure, or to resect conservatively, risking cancer recurrence due to residual malignant cells. A chemo-functionalized implant, capable of physically supporting the void while killing residual cancer cells, would be an attractive solution. Here we describe a novel additively manufactured implant that can be functionalized with chitosan/siRNA nanoparticles. These induce long term gene silencing in adjacent cancer cells without showing toxicity to normal cells. When scaffolds are functionalized with siRNA/chitosan nanoparticles and doxorubicin in combination, their effects synergized leading to cancer cell death. This technology may be used to target resistance genes by RNA interference and thereby re-sensitizing the cancer cells to co-delivered chemotherapy.
ISSN:2046-2069
2046-2069
DOI:10.1039/c5ra23748c